The Journey of a Drug: A Detective's Notes from a Single Pill to Blood Concentration

Two in the morning on the oncology ward: a woman who has just finished a cyclophosphamide infusion presses the call button — her urine has turned pink. In the next bed, an HIV patient has lost three kilograms in a week to diarrhea, and the attending flips open the chart, ready to add a drug extracted from a plant. Three beds further down, an elderly man has just had blood drawn; he needs long-term warfarin, but the dose that suits one patient can be wildly wrong for another. The attending stops the intern: "Before you prescribe, pull his CYP2C9 and VKORC1 genotypes first."

On the surface these three scenes have nothing to do with one another. But once you understand the language of pharmacology, you will see they are all telling the same story — a drug entering the body is a journey. From absorption, through distribution and metabolism, to excretion, at every stop someone is hitting the brakes, someone is stepping on the gas, and someone is taking a wrong turn. General pharmacology is hard precisely because it never asks you to memorize which drug matches which disease; instead, it asks you to reason like a detective, working forward from "why" to "what happens next."

In this volume we open at that small chloride gate in the gut lumen, travel through the cell-cycle battlefield of cancer chemotherapy and the metabolic traps and chelator pairings of drug interactions, and finally land in the core equations of pharmacokinetics (PK). By the end, you will find that every testable point is strung along the same chain of reasoning.

1. The Faucet in the Gut Lumen: One Direction Decides Whether You Are Treating Constipation or Diarrhea

Why Chloride Ions Have the Final Say over Water in the Gut Lumen

🔬 Mechanism, unpacked

Water in the gut lumen does not simply stay because it wants to — it is dragged along by chloride ions. The apical membrane of the intestinal epithelium carries two important chloride channels: cystic fibrosis transmembrane conductance regulator (CFTR) and chloride channel type 2 (ClC-2). Step one: the cell actively pumps chloride into the lumen. Step two: as negative charge accumulates, sodium is drawn in after it. Step three: luminal osmotic pressure rises, and water follows the osmotic gradient in alongside the sodium and chloride. Step four: luminal fluid increases, stool softens, and motility speeds up. Run the process in reverse and everything flips: block chloride secretion, water has no reason to enter the lumen, and diarrhea stops. So constipation calls for "opening" the faucet, and secretory diarrhea calls for "closing" it — opposite directions, but the same causal chain of mechanism.

If you picture the intestinal epithelium as a kitchen sink, CFTR is the main faucet — when it malfunctions in cystic fibrosis, chloride cannot get out and water cannot follow, so sweat turns salty, sputum turns thick, and luminal fluid dries up. ClC-2 is the backup, smaller faucet, sitting on the same apical membrane but normally quiet, waiting to be woken by prostaglandins. Once you understand the relationship between the two faucets, the table below stops being something to memorize and becomes a quick-reference chart you could sketch out yourself.

Drug	Target channel	Direction of Cl⁻ secretion	Result	Indication
Lubiprostone	Activates ClC-2	Promotes (opens the faucet)	Luminal fluid↑, stool softens, motility↑	IBS-C, chronic idiopathic constipation, opioid-induced constipation
Crofelemer	Inhibits CFTR and the calcium-activated chloride channel (CaCC)	Inhibits (shuts the faucet)	Luminal secretion↓, stops diarrhea	Noninfectious diarrhea associated with HIV antiretroviral therapy

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Lubiprostone: The Prostaglandin Derivative That Opens the Backup Faucet

Lubiprostone is a prostaglandin E1 (PGE1) derivative (of the prostone class). Its causal chain is clean and direct: the drug enters the gut lumen → binds ClC-2 on the apical membrane of the intestinal epithelium → the channel opens and chloride floods out → water follows into the lumen → stool softens and motility speeds up → constipation improves. It does not touch CFTR, which is a favorite exam fork. The common side effect is nausea (dose-related, eased by taking the drug with food); a minority of patients develop diarrhea or headache.

Memory hook: Lubi → "lubricate" the gut → relieves constipation; its target is ClC-2.

Crofelemer: The Plant Extract That Turns Down the Main Faucet

Crofelemer is extracted from a South American plant known as "dragon's blood," and is one of the rare oral drugs that is almost not absorbed systemically — once it has done its job in the gut lumen, it simply travels out with the stool, so systemic side effects are minimal. Its mechanism is to inhibit both CFTR and the CaCC channel simultaneously, blocking the intestinal epithelium's ability to pump chloride into the lumen; water is no longer drawn in, and secretory diarrhea stops. Its approved indication is narrow: noninfectious diarrhea in HIV patients receiving antiretroviral therapy (ART) — because this type of diarrhea is usually driven by a drug-induced secretory mechanism, which is exactly what the drug addresses.

⭐ Board-exam essentials

The two gut-fluid chloride-channel drugs

Lubiprostone = PGE1 derivative → activates ClC-2 → promotes secretion and relieves constipation; used for IBS-C, chronic constipation, opioid-induced constipation; the main side effect is nausea (eased with food).
Crofelemer = inhibits CFTR and CaCC → suppresses secretion and stops diarrhea; a plant extract, almost no systemic absorption; used for ART-associated noninfectious diarrhea.
Don't flip the channels: Lubi acts on ClC-2, not CFTR; Crofe acts on CFTR, not ClC-2.
Don't flip the direction: constipation = promote secretion (open); secretory diarrhea = suppress secretion (shut).
Traps: writing lubiprostone's target as CFTR; giving crofelemer to a constipated patient; assuming crofelemer has significant systemic effects (it is in fact almost unabsorbed); overlooking that lubiprostone's nausea is dose-related.

♪ Sing-along text — English rendering of the Mandarin song lyrics

Who really decides how much water sits in the gut lumen — that is the first mystery this section unravels. The answer is not that water simply stays because it wants to; it is dragged along by chloride ions. The apical membrane of the intestinal epithelium has two doors: a big one called CFTR, and a small one called ClC-2. The cell actively pumps chloride into the lumen; as negative charge builds up it draws sodium in after it; sodium and chloride together raise the osmotic pressure of the lumen, and water seeps in along the gradient, so luminal fluid increases, stool softens, and motility speeds up. Run it the other way — turn the chloride valve down — and water has no reason to enter the lumen, so secretory diarrhea stops. Constipation needs the faucet opened; secretory diarrhea needs the faucet turned down. These are the two directions of the same causal chain.

Constipation needs the faucet opened, secretory diarrhea needs the faucet turned down — chloride secretion is the steering wheel of luminal fluid.

The first drug, lubiprostone, is a derivative of prostaglandin E1; it wakes up the normally quiet small faucet, ClC-2. Once the channel opens, chloride floods out, water follows into the lumen, stool softens, and the gut starts moving — so it is used for constipation-predominant IBS, chronic idiopathic constipation, and opioid-induced constipation. It does not touch the big faucet, CFTR, which is the exam's fork in the road; its common side effect is nausea, which is dose-related and eased by taking it with food. If you need a hook, remember the word "lubricate" hidden in its name — lubricating the gut means opening the backup faucet, ClC-2. The second drug, crofelemer, is extracted from a South American plant called dragon's blood; it is one of the rare oral drugs that is almost not absorbed systemically. Its entire working field is the gut lumen, and once it has done its job it leaves with the stool, so systemic side effects are minimal. It inhibits both the big faucet, CFTR, and another channel, the calcium-activated chloride channel, together, so the intestinal epithelium can no longer pump chloride into the lumen; water is held back in the blood, and secretory diarrhea stops. Its approved indication is narrow — noninfectious, drug-induced diarrhea in HIV patients receiving antiretroviral therapy — because that type of diarrhea is driven by exactly this excess-secretion mechanism, which the drug addresses precisely.

Constipation needs the faucet opened, secretory diarrhea needs the faucet turned down — chloride secretion is the steering wheel of luminal fluid.

The exam loves to attack from three angles here. The first is flipping the direction — choosing crofelemer for what is actually constipation, or lubiprostone for what is actually diarrhea. The fix is to first ask whether the patient has too little water or too much, then follow that logic through to opening or closing the faucet. The second is swapping the target channels — writing lubiprostone's target as CFTR, or crofelemer's as ClC-2. This is pure paired memorization, but as long as you remember that Lubi works the small backup faucet and Crofe works the main faucet, you won't get it wrong. The third is absorption — crofelemer is almost not absorbed systemically, so systemic side effects are rare, yet many people assume it acts throughout the body like an ordinary oral drug and misjudge its safety. Treat the gut lumen as a sink, chloride as the faucet, and the drug as merely something that opens or closes it, and every test point in this section strings together into one line.

Constipation needs the faucet opened, secretory diarrhea needs the faucet turned down — chloride secretion is the steering wheel of luminal fluid.

2. The Battlefield of Chemotherapy: Cell Cycle, Prodrugs, Metabolic Traps, and Targeted Agents

Cell-Cycle-Specific or Nonspecific: The First Fork in the Road

Cell-cycle phase	Representative drugs	Mechanism
S phase (DNA synthesis)	Antimetabolites (MTX, 5-FU, 6-MP), irinotecan / topotecan (topoisomerase I inhibition)	Interferes with DNA synthesis
G2 phase	Bleomycin (CCS, arrests at G2)	Free radicals cleave DNA, cell arrests at G2
M phase (spindle)	Taxanes (paclitaxel), ixabepilone (stabilizes microtubules), vinca alkaloids (inhibit polymerization)	Interferes with the mitotic spindle
Nonspecific (CCNS)	Alkylating agents (cyclophosphamide), platinum compounds, anthracyclines	Direct DNA damage

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

This table hides three high-yield forks. First, irinotecan acts in S phase (it inhibits topoisomerase I, topo I) — do not confuse it with the M-phase spindle drugs. Second, ixabepilone belongs to the epothilone class and acts in M phase — its mechanism is microtubule stabilization, the same route as the taxanes; the exam loves to mislabel it as S phase to trap you. Third, bleomycin is one of the few "antitumor antibiotics" clearly classified as CCS, arresting at G2 — completely different from the anthracyclines (doxorubicin, etc.), which are also antibiotics but are CCNS. This is a high-frequency fork.

Cyclophosphamide: The Prodrug That Needs the Liver to "Switch It On" First

The ironclad rule for prevention is doing two things together: MESNA (mercaptoethanesulfonate sodium) plus aggressive hydration. MESNA binds acrolein once it reaches the urine and "dismantles" it into a nontoxic form; aggressive hydration dilutes the toxin and speeds its clearance. The exam loves to ask about the signature toxicity and why MESNA is needed — follow the causal chain "acrolein damages the bladder, MESNA dismantles it," and the answer falls out on its own.

6-MP × Allopurinol: Poisoning When the Garbage Truck Gets Stopped

Visual metaphor: XO is 6-MP's "garbage truck"; allopurinol stops the truck → 6-MP piles up in the street → poisoning. The same script applies to azathioprine (which is metabolized into 6-MP, so it must be reduced in the same way).

Anthracyclines: A Story of Cardiotoxicity and Free Radicals

The anthracyclines include idarubicin, doxorubicin, and daunorubicin; their mechanism is to inhibit topoisomerase II (topo II) → double-strand DNA breaks, while also intercalating into DNA and generating large amounts of free radicals. Their signature toxicity is cumulative-dose dilated cardiomyopathy and heart failure — because cardiac myocytes have relatively weak antioxidant defenses, they collapse under sustained free-radical attack.

Prevention makes for an elegant mechanism question: dexrazoxane is an iron chelator that strips iron out of the myocardium, reducing the free radicals generated by the Fenton reaction, and so protects the heart. When trastuzumab is combined with an anthracycline, cardiotoxicity is additive — another high-frequency trap.

Targeted Agents: The Two Roads of "-nib" and "-mab"

Nail the naming convention first: "-nib" denotes a small-molecule tyrosine kinase inhibitor (TKI), which strikes the intracellular kinase segment of the receptor; "-mab" denotes a monoclonal antibody, which strikes the extracellular segment of the receptor or an extracellular ligand.

Drug	Molecular target	Mechanism / indication
Bevacizumab (-mab)	Vascular endothelial growth factor (VEGF)	Binds VEGF → inhibits tumor angiogenesis; toxicity: hypertension, bleeding, poor wound healing, bowel perforation
Lapatinib (-nib)	HER-2 (and epidermal growth factor receptor, EGFR) tyrosine kinase	Inhibits the intracellular TK → HER-2-positive breast cancer
Trastuzumab (-mab)	Extracellular domain of HER-2	HER-2-positive breast cancer; toxicity: cardiotoxicity (more pronounced with anthracycline combination)
Catumaxomab	Bispecific antibody: binds EpCAM (tumor) and CD3 (T cell) simultaneously	Draws T cells alongside the tumor to kill it; used for malignant ascites

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Other High-Frequency Single-Drug Toxicities

Drug	Signature toxicity
Bleomycin	Pulmonary fibrosis
Cisplatin	Nephrotoxicity, ototoxicity, peripheral neuropathy (hydration + amifostine protect the kidney)
Vincristine	Peripheral neuropathy (vinblastine is the one causing myelosuppression)
Methotrexate	Myelosuppression, mucositis (rescued with leucovorin (folinic acid))
Anthracyclines	Cardiotoxicity (dexrazoxane protects the heart)
Cyclophosphamide	Hemorrhagic cystitis (MESNA)

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

⭐ Board-exam essentials

Chemotherapy must-know checklist

Fork: CCS = antimetabolites / spindle poisons / bleomycin (G2); CCNS = alkylating agents / platinum compounds / anthracyclines.
Cell-cycle localization: irinotecan = S phase (topo I); ixabepilone = M phase (microtubule stabilization); bleomycin = G2 phase.
Cyclophosphamide = a prodrug, requiring CYP450 activation; signature toxicity = hemorrhagic cystitis (acrolein → MESNA).
6-MP is metabolized by XO; combined with allopurinol, it must be reduced to 1/4 dose; the same applies to azathioprine.
Anthracyclines inhibit topo II (not topo I); cardiotoxicity can be prevented with dexrazoxane (an iron chelator).
Bevacizumab = anti-VEGF; lapatinib = anti-intracellular HER-2 TK; trastuzumab = anti-extracellular HER-2; catumaxomab = EpCAM + CD3 bispecific.
Traps: classifying alkylating agents as CCS (wrong — they are CCNS); classifying bleomycin as CCNS (wrong — it is CCS, G2); writing anthracyclines' signature toxicity as pulmonary fibrosis (wrong — that is bleomycin); writing cyclophosphamide's signature toxicity as cardiotoxicity (wrong — it is hemorrhagic cystitis); writing vincristine's signature toxicity as myelosuppression (wrong — that is vinblastine).

♪ Sing-along text — English rendering of the Mandarin song lyrics

The oncology attending draws a clock face on the whiteboard, splitting anticancer drugs into two great camps. Drugs that pick a phase are called cell-cycle specific, because the cancer cell has to arrive at that particular compartment before the drug can kill it — so they are especially effective against rapidly dividing cells, but their effect has a ceiling: no amount of extra dose will save cells that are not in that compartment. Drugs that do not pick a phase are called nonspecific; they damage DNA directly and act throughout every phase, so they are dose-dependent — alkylating agents, platinum compounds, and anthracyclines all sit on this side. This first classification makes clear, at a glance, how dosing logic should proceed.

Chemotherapy splits into two roads: the phase-picking road has a ceiling, the phase-blind road follows the dose, and a prodrug must be activated before it can take the field.

Place every drug at its corresponding position on the clock, and the exam's favorite traps fall apart on their own. First, irinotecan acts in the synthesis phase, because it inhibits topoisomerase I and interferes with DNA synthesis — do not confuse it with the spindle drugs of the division phase. Second, ixabepilone acts in the division phase; it shares a route with the taxanes, stabilizing microtubules so the cell cannot split apart, but many people mistakenly place it in the synthesis phase. Third, bleomycin is one of the few antitumor antibiotics clearly classified as cell-cycle specific, arresting at G2 — completely different from the anthracyclines, which are also antibiotics but are nonspecific; the two are frequently confused. Cyclophosphamide is the textbook prodrug: it has no activity of its own and must reach the liver to be oxidized by cytochrome P450 before it becomes active. The resulting active metabolite cross-links DNA to kill cancer cells, but the reaction also produces a toxic byproduct, acrolein, which irritates the bladder mucosa on its way out in the urine — that is hemorrhagic cystitis. Prevention relies on mercaptoethanesulfonate sodium binding the acrolein, plus aggressive hydration to dilute it. So when the exam asks for the signature toxicity, the answer is always hemorrhagic cystitis, never cardiotoxicity — cardiotoxicity is the anthracyclines' signature.

Chemotherapy splits into two roads: the phase-picking road has a ceiling, the phase-blind road follows the dose, and a prodrug must be activated before it can take the field.

6-mercaptopurine is cleared by the garbage truck called xanthine oxidase, and as it happens, the gout drug allopurinol works by inhibiting exactly this truck. So when the two drugs collide, 6-mercaptopurine has no truck left to haul it away, piling up to three or four times its normal blood level, and severe myelosuppression erupts; when used together, the dose must be cut to one-quarter of the original to stay safe. Azathioprine is metabolized into 6-mercaptopurine, so it must be reduced the same way. This is the licensing exam's favorite drug-interaction question, and at its core it is simply two drugs competing for the same metabolic enzyme. Anthracyclines such as doxorubicin inhibit topoisomerase II, causing double-strand DNA breaks while also generating large amounts of free radicals; cardiac myocytes have relatively weak antioxidant capacity, so they collapse under sustained free-radical attack, making the signature toxicity cumulative-dose dilated cardiomyopathy and heart failure. Prevention can rely on dexrazoxane, an iron chelator that strips iron out of the myocardium and reduces free-radical generation. Combining trastuzumab with an anthracycline makes cardiotoxicity additive — another frequently tested trap.

The naming of targeted drugs actually hides the answer. Drugs ending in "-nib" are small-molecule tyrosine kinase inhibitors that strike the intracellular kinase segment of the receptor — for instance, lapatinib strikes the intracellular kinase of HER-2 to treat breast cancer. Drugs ending in "-mab" are monoclonal antibodies that strike the extracellular segment of the receptor or an extracellular ligand — for instance, bevacizumab binds vascular endothelial growth factor to starve the tumor's blood vessels, and trastuzumab strikes the extracellular domain of HER-2, hitting a different segment from lapatinib but used in the same patient population. One oddball is catumaxomab, a bispecific antibody that holds EpCAM on the tumor with one hand and CD3 on the immune cell with the other, drawing T cells alongside the tumor to kill it, used for malignant ascites. The signature toxicities of the other single agents each have their own story you can reason through: bleomycin is pulmonary fibrosis, cisplatin is nephrotoxicity, ototoxicity, and peripheral neuropathy, vincristine is peripheral neuropathy while vinblastine is the one causing myelosuppression, and methotrexate's myelosuppression and mucositis can be rescued with leucovorin. Tie every drug to its mechanism and toxicity along the causal chain, and when the question arrives you will not need to memorize it — you will simply reason it through.

Chemotherapy splits into two roads: the phase-picking road has a ceiling, the phase-blind road follows the dose, and a prodrug must be activated before it can take the field.

3. Open Rivalry and Hidden Scheming Among Drugs: Metabolic Traps, Antidote Pairings, and Acetaldehyde Accumulation

Kinetics or Dynamics: Sorting Out the Levels of Interaction First

A drug-drug interaction (DDI) always splits first into two levels. A pharmacokinetic (PK) interaction changes the "blood concentration" — it affects any single stop along ADME (absorption, distribution, metabolism, excretion); a pharmacodynamic (PD) interaction changes the "drug effect" — additive at the same receptor (two antihypertensives pushing blood pressure down together) or opposing at different receptors (physiologic antagonism).

In one line: PK means "the amount of drug is changed"; PD means "the drug's effect is changed."

CYP450 Metabolic Interactions: Inhibition Causes Gridlock, Induction Clears the Shelves

Visual metaphor: clearance (Cl) is the kitchen's drainage rate — how large a volume of plasma is completely cleared of drug each minute; volume of distribution (Vd) is the house the drug lives in — a large Vd means the drug has run off to hide in the tissues (little left in the blood, like living in a big house out in the suburbs), while a small Vd means most of the drug stays in the blood (like living in a small studio).

CYP inhibitors: cimetidine, ketoconazole, erythromycin, grapefruit juice (specifically targeting CYP3A4) → substrate toxicity.
CYP inducers: rifampin, phenytoin, carbamazepine, barbiturates, chronic alcohol use → substrate failure (classic examples: oral contraceptive failure, warfarin failure).

Mnemonic: an inhibitor lets the drug "gridlock" (concentration piles up, toxicity); an inducer lets the drug "clear out" (concentration drains away, failure).

Manipulating Urine pH to Speed Excretion: The Causal Chain of Ion Trapping

In one line: "treat acid poisoning with base" — give sodium bicarbonate for acidic-drug poisoning.

Chelator Pairings for Heavy-Metal Poisoning: Mismatch and You've Hit the Trap

Poisoning metal	First-line chelator	Key point / trap
Arsenic	DMSA (succimer), DMPS (unithiol), dimercaprol (BAL)	Penicillamine is not used for arsenic poisoning (a frequently tested reversal trap)
Lead	EDTA (CaNa₂EDTA), DMSA, dimercaprol	Oral DMSA is first-line for lead poisoning in children
Mercury	DMSA, DMPS, dimercaprol	—
Copper (Wilson disease)	Penicillamine, trientine	This is penicillamine's true stage
Iron	Deferoxamine	—

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The licensing exam loves to slip in the reversed option of giving penicillamine for arsenic poisoning. Penicillamine's true home is copper poisoning in Wilson disease; arsenic calls for DMSA, DMPS, or dimercaprol.

Disulfiram-like Reaction: Acetaldehyde Stuck and Accumulating

Other drugs that trigger the same reaction (this group is a high-frequency, easy-marks question): metronidazole; cephalosporins bearing an NMTT (N-methylthiotetrazole) side chain such as cefamandole / cefotetan; chlorpropamide; and griseofulvin.

Other High-Frequency Single-Drug Toxicities and Pre-Treatment Screening

Cimetidine (an H2 blocker): has an antiandrogen effect → long-term use causes impotence and gynecomastia; it is also a CYP inhibitor with a long list of interactions.
Famotidine: among the H2 antagonists it has the strongest acid-suppressing potency, and it lacks cimetidine's antiandrogen effect and CYP-inhibition problems. It is the clinical first-choice H2 blocker.
Abacavir: HLA-B*5701 must be tested before treatment; it is contraindicated if positive, or else it triggers a fatal hypersensitivity reaction. Take care not to confuse this with carbamazepine's HLA-B*1502.

⭐ Board-exam essentials

Drug interaction and antidote must-know checklist

PK ≠ PD: PK changes blood concentration (ADME); PD changes drug effect (additive or opposing at the receptor).
CYP inhibitors (cimetidine, ketoconazole, erythromycin, grapefruit juice) → substrate toxicity; CYP inducers (rifampin, phenytoin, carbamazepine, barbiturates, chronic alcohol) → substrate failure (contraceptive failure, warfarin failure).
Treat acid poisoning with base: give NaHCO₃ to alkalinize the urine for acidic-drug poisoning; the weak acid ionizes → is not reabsorbed → excretion accelerates.
Chelator pairings: arsenic → DMSA / DMPS / BAL (not penicillamine); lead → EDTA / DMSA; copper (Wilson) → penicillamine; iron → deferoxamine.
Disulfiram-like reaction = ALDH inhibition → acetaldehyde accumulation; other drugs that cause it: metronidazole, cefamandole / cefotetan (NMTT-bearing cephalosporins), chlorpropamide, griseofulvin.
Cimetidine → antiandrogen effect + CYP inhibition (impotence, gynecomastia); famotidine has the strongest acid suppression and none of these problems.
Test HLA-B*5701 before abacavir; don't confuse it with HLA-B*1502 (carbamazepine).
Traps: answering "neutralize blood acid" for acidic-drug poisoning (the correct answer is alkalinizing the urine to accelerate excretion); giving penicillamine for arsenic; mistaking cimetidine for a side-effect-free stomach drug; writing abacavir's HLA as 1502.

♪ Sing-along text — English rendering of the Mandarin song lyrics

A drug-drug interaction always splits first into two levels. A pharmacokinetic interaction changes the blood concentration, affecting any one of the four stops — absorption, distribution, metabolism, excretion; a pharmacodynamic interaction changes the drug effect, for example two antihypertensives adding together, or a benzodiazepine adding to alcohol's central depression. In one line: kinetics changes the amount of drug, dynamics changes the drug's effect. The liver's cytochrome P450 is the body's largest metabolic kitchen; if another drug inhibits it, the substrate drug gets stuck in gridlock, its blood concentration piles up, and it heads toward toxicity; if another drug induces it, the substrate is cleared too fast, its concentration drains away, and its efficacy fails. Classic inhibitors include cimetidine, ketoconazole, erythromycin, and grapefruit juice; classic inducers include rifampin, phenytoin, carbamazepine, barbiturates, and chronic alcohol use — this is exactly why they cause oral contraceptives and warfarin to fail. Picture clearance as the kitchen's drainage rate, and volume of distribution as the house the drug lives in; link the two to the half-life, which equals 0.693 times the volume of distribution divided by clearance — the slower the drainage or the bigger the house, the longer the half-life.

Inhibition gridlocks the drug, induction clears it out; treat acid poisoning with base, and give arsenic no penicillamine.

The ironclad rule of the renal tubule is just as simple: an ionized drug cannot cross the cell membrane and is swept away in the urine, while a nonionized drug is instead reabsorbed back into the blood. So for acidic-drug poisoning such as aspirin or phenobarbital, give sodium bicarbonate to alkalinize the urine; the weak acid ionizes in the alkaline environment, is not reabsorbed, and clears faster. Conversely, to speed the excretion of a basic drug you would acidify the urine, though this is rarely done clinically. Remember "treat acid poisoning with base," and you will never flip the direction into treating acid poisoning with acid or base poisoning with base. Chelator pairing for heavy-metal poisoning is the licensing exam's easy-marks question that is nonetheless the easiest to get wrong — the key is not to misuse penicillamine. Arsenic poisoning calls first for DMSA, DMPS, or dimercaprol; lead poisoning calls for EDTA or DMSA; mercury poisoning calls for DMSA, DMPS, or dimercaprol; copper poisoning — that is, Wilson disease — is the only one that calls for penicillamine or trientine; iron poisoning calls for deferoxamine. The exam loves to slip you the wrong pairing of penicillamine for arsenic poisoning; just remember the line "arsenic gets no penicillamine, only copper gets penicillamine."

Inhibition gridlocks the drug, induction clears it out; treat acid poisoning with base, and give arsenic no penicillamine.

The story of disulfiram, a drug that supports abstinence, is an elegant metabolic chain. Alcohol is oxidized in the liver by alcohol dehydrogenase into acetaldehyde, and acetaldehyde is then oxidized by acetaldehyde dehydrogenase into acetic acid and cleared — a two-step assembly line. What disulfiram inhibits is the second step's acetaldehyde dehydrogenase, so acetaldehyde gets stuck and accumulates, causing nausea, vomiting, flushing, palpitations, headache, and hypotension; the patient is frightened enough that the next time they smell alcohol, they are afraid — which is exactly the principle behind its use in supporting abstinence. Other drugs that trigger the same reaction include metronidazole, cephalosporins with a specific side chain such as cefamandole and cefotetan, chlorpropamide, and griseofulvin — this group is a high-frequency, easy-marks question: see a patient on these drugs who drinks and flushes, follow the causal chain of inhibited acetaldehyde dehydrogenase, and the answer pops out. Cimetidine, although it is an H2 blocker used to treat peptic ulcers, carries an antiandrogen side effect; long-term use causes impotence and gynecomastia in men, and it is itself a cytochrome P450 inhibitor with a long list of interactions — so clinically, famotidine is now preferred, since it has the strongest acid-suppressing potency and none of cimetidine's antiandrogen problems, making it the first-choice H2 blocker.

The last point that is easy to overlook but always tested is pre-treatment genetic screening. Abacavir is a first-line drug in HIV treatment, but patients carrying the HLA-B*5701 allele develop a fatal hypersensitivity reaction, so HLA-B*5701 must always be tested before treatment, and a positive result contraindicates the drug. Easily confused with it is the carbamazepine group, which requires testing for HLA-B*1502 — especially in Asian populations — to avoid Stevens-Johnson syndrome. Hold on to three main threads and this whole section falls into place: kinetics changes the amount of drug, dynamics changes the drug's effect; CYP inhibition causes gridlock and toxicity, CYP induction clears the shelves and causes failure; and among the antidote pairings, penicillamine goes only to copper — never hand it to arsenic.

Inhibition gridlocks the drug, induction clears it out; treat acid poisoning with base, and give arsenic no penicillamine.

4. Behind the Equations of Pharmacokinetics: From Absorption to Antagonism, Stringing Every Question into One Causal Chain

Biotransformation: Turning Lipophilic into Water-Soluble So It Can Be Cleared

Phase	Reaction	Representative enzymes	Characteristics
Phase I	Oxidation, reduction, hydrolysis (adds functional groups such as -OH, -NH₂)	CYP450	Product may still be active, and can even activate a prodrug
Phase II	Conjugation: glucuronidation, sulfation, acetylation, GSH conjugation	UGT, NAT, GST	Usually inactivates the drug and greatly increases water solubility

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

In one line: Phase I opens a door (installs a handle); Phase II attaches a label (a large group) and ships the drug out of the body. Note that biotransformation is not necessarily "detoxification" — some metabolites are in fact more toxic (such as cyclophosphamide's acrolein), and some prodrugs actually need the liver to "switch them on" before they work.

Henderson-Hasselbalch: Which Way Weak Acids and Weak Bases Are Absorbed

Equation: for a weak acid, pH = pKa + log([A⁻]/[HA]); for a weak base, pH = pKa + log([B]/[BH⁺]).

Core concept: a drug can cross the cell membrane and be absorbed only when it is nonionized (neutral); the ionized form is trapped where it is (ion trapping).

A worked example you must know by heart: a weak acid with pKa = 6, placed at pH 4 (two units below its pKa) → the log term = −2 → [A⁻]:[HA] = 1:100 (ionized : nonionized) → overwhelmingly nonionized in the acidic stomach → readily absorbed.

Mnemonic: "acid in acid, base in base — nonionized" — a weak acid is nonionized in an acidic environment, and a weak base is nonionized in a basic environment (readily absorbed either way). This is also the mirror-image application of "treat acid poisoning with base": put a weak acid into alkaline urine on purpose, so that it ionizes and gets flushed out.

Inhaled Anesthetics: The Larger the Blood:Gas Partition Coefficient, the Slower

Visual metaphor: think of the inhaled anesthetic as a salesman, and the blood as a lobby that loves to keep guests around. The clingier the lobby (a large coefficient), the longer it takes the salesman to fight through it and reach his destination — the brain — to finish the job.

Four Types of Antagonism: Tell Them Apart by the Curve

Antagonism type	Binds the receptor?	Effect on the agonist curve	Reversible by raising agonist concentration?
Competitive antagonism	Yes (same site, reversible)	Curve shifts right, maximal efficacy unchanged	Yes (overcome by raising the dose)
Noncompetitive antagonism	Yes (irreversible, or a different site)	Maximal efficacy decreases	No (raising the agonist cannot rescue it)
Chemical antagonism	No (does not need to bind the receptor)	Binds the drug directly to inactivate it (e.g., protamine neutralizing heparin)	Not applicable
Physiologic antagonism	No (acts on different receptors to produce an opposing physiologic effect)	E.g., epinephrine versus histamine	Not applicable

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

In one line: competitive = shifts right, reversible (a contest of concentration); noncompetitive = lowers the ceiling (a contest you cannot win).

Bioavailability: An Intravenous Dose Is Always 100%

Bioavailability (F) is the fraction of a drug that reaches the systemic circulation. Intravenous (IV) administration gives F = 100%, the highest of any route — it enters the blood directly, with no first-pass effect. Oral F is reduced below 100% by absorption rate plus hepatic first-pass metabolism. Formula: F = (oral AUC / IV AUC) × (dose correction).

Think of volume of distribution as "the house the drug lives in" and clearance as "the kitchen's drainage rate"; the half-life is t½ = 0.693 × Vd / Cl — the larger the Vd or the smaller the Cl, the longer the half-life.

Elimination Kinetics: First-Order vs. Zero-Order — Why Phenytoin Needs Blood-Level Monitoring

Type	Elimination rate	Half-life	Representative drugs
First-order kinetics	Proportional to blood concentration (a constant "fraction" is eliminated)	Fixed (independent of concentration)	Most drugs
Zero-order kinetics	A fixed amount is eliminated (enzyme saturated, independent of concentration)	Lengthens as concentration rises, no fixed value	Ethanol, phenytoin (high dose), aspirin (high dose)

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Mnemonic: "PEA" goes zero-order — Phenytoin, Ethanol, Aspirin (at high dose, once saturated, switching to zero-order). A zero-order drug can have its blood concentration surge from a small increase in dose (prone to toxicity) — the fundamental reason phenytoin requires routine blood-level monitoring.

Warfarin Pharmacogenomics: Two Genes Decide the Dose

Gene	Role	Effect
CYP2C9	Responsible for warfarin's oxidative metabolism (clearance)	Variant → slower metabolism → prone to bleeding, dose reduction needed
VKORC1 (vitamin K epoxide reductase complex 1)	Warfarin's site of action	Variant → altered sensitivity to warfarin

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Mnemonic: CYP2C9 handles "clearing it away"; VKORC1 is "the target it hits" — one governs metabolism, the other governs drug effect. A frequently tested trap: mistakenly choosing CYP3A4 or CYP2D6.

🦦

PipThe patient's phenytoin level is a bit low, so I'll raise the dose by 25% and check again in a few days — it's first-order kinetics, right, so whatever you add, it goes up by that much!

🐻‍❄️

BarnabyThat's exactly the trap. Within the therapeutic range, phenytoin is already following zero-order kinetics — the metabolizing enzyme is already saturated, so a small increase in dose lets the blood concentration surge, potentially rocketing from the therapeutic range straight into the toxic range (nystagmus, ataxia, coma). This is exactly why phenytoin must have its blood level monitored. Zero-order drugs spell PEA: Phenytoin, Ethanol, Aspirin (at high dose) — matching the fixed rate behind "you can't drive after drinking": blood alcohol falls by a fixed amount per hour, regardless of how much you drank.

⭐ Board-exam essentials

Pharmacokinetics must-know checklist

Purpose of biotransformation: convert a lipophilic drug to water-soluble for excretion; not necessarily detoxification (a prodrug instead needs to be activated).
Phase I = CYP450 oxidation, reduction, hydrolysis; Phase II = conjugation (attaching a large group to inactivate the drug and increase water solubility).
Henderson-Hasselbalch: a weak acid with pKa = 6 at pH 4 → ionized : nonionized = 1:100; "acid in acid, base in base — nonionized, readily absorbed."
Inhaled anesthetics: a large blood:gas partition coefficient → slow induction, slow recovery (halothane); small → fast (N₂O, desflurane).
Four types of antagonism: competitive shifts the curve right and is reversible; noncompetitive lowers the ceiling and is irreversible; chemical does not need to bind the receptor (protamine neutralizing heparin); physiologic acts through different receptors.
The route with the highest bioavailability = IV (100%); oral bioavailability is affected by absorption plus first-pass metabolism.
Zero-order kinetics drugs = PEA (phenytoin, ethanol, high-dose aspirin); the zero-order half-life lengthens as concentration rises and has no fixed value.
Half-life t½ = 0.693 × Vd / Cl; a large Vd or small Cl → a long half-life.
Warfarin's two genes = CYP2C9 (metabolism) + VKORC1 (target); don't mistakenly choose CYP3A4 or CYP2D6.
Traps: treating a zero-order drug as first-order (a small dose increase causes a large surge); reversing the direction of the blood:gas partition coefficient (mistakenly thinking large means fast); imagining chemical antagonism requires binding the receptor; calculating a weak acid at pKa = 6, pH = 4 as 100:1 (the direction reversed); treating all biotransformation as "detoxification" (a prodrug is instead activated).

♪ Sing-along text — English rendering of the Mandarin song lyrics

The emergency department admits a patient with phenytoin toxicity: adding just one extra pill sent the blood concentration surging to three times normal, with nystagmus, ataxia, and slurred speech, and only when the resident checked the textbook did it come back to him that this drug is eliminated by zero-order kinetics, where a small increase in dose causes a surge. Next door, anesthesiology is using desflurane for an outpatient surgery, for a simple reason: its blood:gas partition coefficient is small, so induction is fast and recovery is fast too. Both departments are running on the same set of pharmacokinetic equations, and this section is about taking that set of equations apart. The core purpose of biotransformation is to convert a lipophilic drug into a water-soluble metabolite so it can be excreted by the kidney or bile, but it is not necessarily detoxification — some metabolites are in fact more toxic, and some prodrugs cannot work at all without being switched on by the liver. Phase I is oxidation, reduction, and hydrolysis, with cytochrome P450 as the lead actor; the product may still be active, and a prodrug may even be activated at this very step. Phase II is conjugation — attaching glucuronic acid, sulfate, an acetyl group, or glutathione to ship the drug out of the body, usually inactivating it and greatly increasing its water solubility. Remember it as: Phase I opens a door and installs a handle, Phase II attaches a label and ships it out. The absorption of weak acids and weak bases is worked out from the Henderson-Hasselbalch equation. The key point is that a drug can cross the cell membrane and be absorbed only when it is nonionized; the ionized form is trapped where it is. One example you must know by heart: a weak acid with a dissociation constant of six, placed in a stomach at pH four, is two log units away, so ionized to nonionized is one to a hundred — the nonionized form makes up the overwhelming majority, and it is readily absorbed in the stomach, which also matches the mnemonic "acid in acid, base in base, nonionized." Its mirror image is treating acid poisoning with base: put an acidic drug into alkaline urine on purpose, letting it ionize and get flushed away, speeding its excretion. The key to inhaled anesthetics is the blood:gas partition coefficient. A large coefficient means the gas loves to dissolve in blood, so it takes a long time for the brain to receive a high enough partial pressure, making induction slow and recovery slow too — halothane is like this. A small coefficient means the gas does not dissolve much in blood, so blood partial pressure rises quickly, giving fast induction and fast recovery — both desflurane and nitrous oxide are like this. Picture the gas as a salesman and the blood as a lobby: the clingier the lobby, the harder it is for the salesman to fight through to his destination, the brain — keep that direction in the metaphor and you will not get it wrong.

Biotransformation turns lipophilic into water-soluble so it can be cleared; a small blood:gas partition coefficient means fast induction; a small increase in a zero-order drug causes a large surge.

The four types of antagonism can be told apart just by looking at the curve. Competitive antagonism binds the same site, reversibly, and shifts the agonist's curve to the right, but the maximal efficacy stays the same, so raising the agonist's concentration can push it back. Noncompetitive antagonism binds irreversibly, or at a different site, pressing down the ceiling of the curve — the maximal efficacy falls, and no amount of added agonist can rescue it. Chemical antagonism does not bind the receptor at all; the two drugs simply meet and inactivate each other directly, as when protamine neutralizes heparin. Physiologic antagonism acts through different receptors but produces opposing physiologic effects, as with epinephrine against histamine — in anaphylactic shock, epinephrine constricts blood vessels while an antihistamine blocks the receptor instead. Of these four types, the most frequently tested distinction is the curve behavior of competitive versus noncompetitive antagonism; remember competitive as a reversible rightward shift and noncompetitive as a lowered ceiling, and you are set. For bioavailability, an intravenous injection is always one hundred percent, because it enters the blood directly with no first-pass effect, whereas an oral dose is discounted by both absorption rate and hepatic first-pass metabolism, so an oral dose is always less than one hundred percent.

Biotransformation turns lipophilic into water-soluble so it can be cleared; a small blood:gas partition coefficient means fast induction; a small increase in a zero-order drug causes a large surge.

Elimination kinetics is the most important test point in this section. Most drugs follow first-order kinetics: a fixed proportion is metabolized away, and the half-life is fixed, independent of concentration. A small handful of drugs follow zero-order kinetics: a fixed amount is metabolized away, and the half-life lengthens as concentration rises, because the metabolizing enzyme is already saturated and there is a ceiling on how much it can carry away. The representative drugs spell out PEA: phenytoin, ethanol, high-dose aspirin. The reason phenytoin absolutely must have its blood level monitored is that, within the therapeutic range, it is already zero-order — a small increase in dose can send the blood concentration surging from therapeutic straight into toxic, bringing nystagmus, ataxia, even coma. The fact that you cannot drive after drinking follows the same logic: blood alcohol falls by a fixed amount per hour, regardless of how much you drank. Picture the volume of distribution as the house the drug lives in — a large volume means the drug has run off to hide in the tissues, leaving little in the blood; picture clearance as the kitchen's drainage rate — how large a volume of plasma is cleared of drug each minute. The half-life equals 0.693 times the volume of distribution divided by clearance, so the larger the volume of distribution or the smaller the clearance, the longer the half-life. Finally, personalizing the dose of warfarin depends mainly on two genes: CYP2C9 governs its oxidative metabolism and clearance, and VKORC1 is the target enzyme it acts on. A CYP2C9 variant slows metabolism, raising bleeding risk and requiring dose reduction; a VKORC1 variant alters sensitivity — you need to look at both together to get it right. The exam loves to slip in CYP3A4 or CYP2D6 to trick you; neither has anything to do with warfarin, so do not pick them by mistake.

Biotransformation turns lipophilic into water-soluble so it can be cleared; a small blood:gas partition coefficient means fast induction; a small increase in a zero-order drug causes a large surge.